A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer

BACKGROUND: Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended phase II dose (RPTD) for the combination of capecitabine and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Strickler, John H., Rushing, Christel N., Niedzwiecki, Donna, McLeod, Abigail, Altomare, Ivy, Uronis, Hope E., Hsu, S. David, Zafar, S. Yousuf, Morse, Michael A., Chang, David Z., Wells, James L., Blackwell, Kimberly L., Marcom, P. Kelly, Arrowood, Christy, Bolch, Emily, Haley, Sherri, Rangwala, Fatima A., Hatch, Ace J., Nixon, Andrew B., Hurwitz, Herbert I.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6824108/
https://ncbi.nlm.nih.gov/pubmed/31675952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6234-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados